17 September 2021 : Original article
Immunological Results of Long-Term Use of Mammalian Target of Rapamycin (mTOR) Inhibitors and Its Effects on Renal Graft Functions
Mehmet Tanrısev1ABCDEF*, Tülay Ayna Kılıçaslan2CD, Hülya Çolak1BFG, Sibel Ersan1BD, Banu Yılmaz1BFG, Alper Alp3B, Cem Tuğmen4BC, Bahar Engin Sevgili
5E
DOI: 10.12659/AOT.932434
Ann Transplant 2021; 26:e932434
Table 3 Comparing pre- and post-transplant immunological variables between study groups.
| Variables | mTOR group (n=37)n (%) | CNI group (n=52)n (%) | p |
|---|---|---|---|
| Pretransplant PRA positivities | 4 (11.1) | 10 (20) | 0.240 |
| Pretransplant PRA I positivities | 4 (11) | 7 (14) | 0.260 |
| Pretransplant PRA II positivities | 3 (8.7) | 7 (14) | 0.260 |
| Post-transplant PRA positivities | 12 (33) | 13 (27) | 0.390 |
| Post-transplant PRA I positivities | 3 (8.3) | 7 (14.6) | 0.670 |
| Post-transplant PRA II positivities | 8 (22) | 9 (18) | 0.900 |
| Post-transplant PRA-A positivities | 0 (0) | 3 (6.3) | 0.160 |
| Post-transplant PRA-B positivities | 4 (11.1) | 5 (10.4) | 0.500 |
| Post-transplant PRA-DR positivities | 2 (5.6) | 1 (2.1) | 0.570 |
| Post-transplant PRA-DQ positivities | 7 (19.4) | 9 (18.8) | 0.500 |
| Post-transplant DSA positivities | 6 (16.7) | 6 (12.5) | 0.290 |
| Post-transplant non-DSA positivities | 7 (19.4) | 10 (20) | 0.720 |
| Pearson’s or Fisher’s exact chi-square tests were used. P | |||